Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

著者: Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer, Dominik Heinzmann, Bert Lum, Sung‐Bae Kim, Tadeusz Pieńkowski, Mikhail Lichinitser, Semiglazov Vf, Bohuslav Melichar, Christian Jackisch - The Lancet 2012 被引用: 346